7 Results for "

immune synapse

" in MedChemExpress (MCE) Product Catalog:
Products (7)

7 Results for "immune synapse" in MCE Product Catalog:

1
1 Cited Publications
Cat. No.: HY-134261A
Synonyms: 8-Bromoadenosine-5'-O-diphosphoribose disodium
8-Br-ADPR disodium (8-Bromoadenosine-5'-O-diphosphoribose) is a TRPM2 inhibitor and ADPR signaling pathway antagonist. 8-Br-ADPR disodium inhibits glucagon-mediated nuclear calcium signaling and downstream CaMKII/CREB phosphorylation by blocking ADPR-induced TRPM2 activation. 8-Br-ADPR disodium significantly reduces gluconeogenic gene expression and blood glucose levels in diabetic models. 8-Br-ADPR disodium effectively blocks ADPR-mediated calcium signal transduction in NK cells, inhibits immune synapse formation, granzyme B release and cytolytic activity against melanoma cells. 8-Br-ADPR disodium is widely used in studies related to diseases such as diabetes, melanoma and lymphoma .
loading...
    loading...
Cat. No.: HY-P99618
CAS No.: 2377419-89-9
Synonyms: IBI315; BH2950
Target:  

EGFR PD-1/PD-L1

Research Areas:  

Cancer

Fidasimtamab is a bispecific antibody targeting human epidermal growth factor receptor 2 (Her2) and programmed death protein 1 (PD-1), with a Ka of 3.55e-10 M for human Her2 and a Ka of 1.17e-9 M for human PD-1. Fidasimtamab cross-links Her2-positive tumor cells with PD-1-positive T cells to form immune synapses, blocks PD-1-ligand interactions, preserves antibody-dependent cellular cytotoxicity, induces gasdermin B (GSDMB)-mediated pyroptosis, and activates T cells. Fidasimtamab is applicable to relevant research on Her2-positive gastric cancer .
loading...
    loading...
Cat. No.: HY-P99757
CAS No.: 2278244-14-5
Synonyms: Hu3F8-BsAb

Target:  

CD3

Research Areas:  

Cancer

Nivatrotamab (Hu3F8-BsAb) is a bispecific antibody targeting GD2 and CD3, with KD values of 5.8 nM and 194 nM, respectively. Nivatrotamab redirects T cells to tumor sites and activates immune synapses, thereby mediating antibody-dependent T cell-mediated cytotoxicity. Nivatrotamab induces specific tumor cytotoxicity, stimulates the release of Th1 cytokines and promotes immune cell infiltration into tumors. In addition, its Fc segment deglycosylation design effectively prevents complement activation and cytokine storm. Nivatrotamab can be widely used in research related to various solid tumors, including melanoma, neuroblastoma, osteosarcoma, small cell lung cancer, breast cancer, Ewing's sarcoma, colon cancer, ovarian cancer and rhabdomyosarcoma .
loading...
    loading...
Cat. No.: HY-134261
CAS No.: 59259-77-7
Synonyms: 8-Bromoadenosine-5'-O-diphosphoribose
Target:  

TRP Channel CaMK

Research Areas:  

Metabolic Disease Cancer

8-Br-ADPR (8-Bromoadenosine-5'-O-diphosphoribose) is a TRPM2 inhibitor and ADPR signaling pathway antagonist. 8-Br-ADPR inhibits glucagon-mediated nuclear calcium signaling and downstream CaMKII/CREB phosphorylation by blocking ADPR-induced TRPM2 activation. 8-Br-ADPR significantly reduces gluconeogenic gene expression and blood glucose levels in diabetic models. 8-Br-ADPR effectively blocks ADPR-mediated calcium signal transduction in NK cells, inhibits immune synapse formation, granzyme B release and cytolytic activity against melanoma cells. 8-Br-ADPR is widely used in studies related to diseases such as diabetes, melanoma and lymphoma .
loading...
    loading...
Cat. No.: HY-185659
CAS No.: 1596134-78-9
Target:  

CD22 Apoptosis Akt ERK

Research Areas:  

Inflammation/Immunology

6'-BPANeuGc is a CD22-targeting ligand. 6'-BPANeuGc suppresses BCR activation, recruits CD22 to B cell immunological synapses, initiates inhibitory signals, induces B cell apoptosis. 6'-BPANeuGc inhibits calcium flux, and inhibits Akt and Erk activation. 6'-BPANeuGc can be used for research on immune system diseases .
loading...
    loading...
Cat. No.: HY-P992540
Research Areas:  

Cancer

IBI389 is an anti-Claudin18.2 × CD3 bispecific antibody. IBI389 binds CD3 and Claudin18.2 to engage T cells, induce immune synapse formation, and redirect T cell killing of Claudin18.2-positive tumors. IBI389 increases intratumoral CD3 +/CD8 + T cells, an immuno-inflammatory phenotype, shortens tumor-T cell distance, compensatorily increases regulatory T cells, and elevates IL-2/IFN-γ; IL-4/IL-10/IL-17A/TNF-α are decreased. IBI389 can be used in gastric cancer-related research .
loading...
    loading...
Cat. No.: HY-P992524
Target:  

CD3

Research Areas:  

Cancer

PF-07260437 is a bispecific monoclonal antibody targeting B7-H4 and CD3, with Kd values of 63.5 nM and 66.75 nM against human and cynomolgus monkey CD3, respectively. PF-07260437 simultaneously binds B7-H4 on tumor cells and the CD3ε subunit in the T cell receptor complex, forming a tumor cell-bispecific antibody-T cell trimer. This process establishes an immune synapse and initiates non-MHC-dependent T cell activation, proliferation, and release of cytotoxic molecules such as granzyme B to kill tumor cells. PF-07260437 can be used in research related to advanced or metastatic breast cancer, ovarian cancer, and endometrial cancer .
loading...
    loading...